Investment
Joined as a new investor in Claris Bio's $118M Series B financing to advance a treatment for limbal stem cell deficiency.
Claris Bio
7 milestones· JAN 2026 – JUL 2026
Milestone
Portfolio company Allotera Therapeutics (formerly Wugen) closed a $35M financing to advance off-the-shelf CAR-T therapies.
Allotera Therapeutics
JUL 8, 2026
Milestone
Portfolio company BridgeBio submitted an NDA to the FDA for Encaleret for individuals living with ADH1.
BridgeBio
MAY 12, 2026
Milestone
Portfolio company Compass Pathways was granted an FDA NDA rolling review and awarded a Commissioner's National Priority Voucher.
Compass Pathways
APR 24, 2026
Milestone
Portfolio company BridgeBio submitted an NDA to the FDA for BBP-418 for individuals living with LGMD2I/R9.
BridgeBio
MAR 30, 2026
Milestone
Portfolio company Compass Pathways announced the exercise of $200M in outstanding warrants.
Compass Pathways
FEB 26, 2026
Milestone
Portfolio company Veradermics priced an upsized initial public offering.
Veradermics
FEB 3, 2026
Milestone
Portfolio company Monte Rosa Therapeutics priced a $300M underwritten public offering.
Monte Rosa Therapeutics
JAN 8, 2026